



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Fang Wu
✉ wufang4461@csu.edu.cn

†These authors have contributed equally to this work

SPECIALTY SECTION
This article was submitted to
Cancer Immunity
and Immunotherapy,
a section of the journal
Frontiers in Oncology

RECEIVED 10 February 2023
ACCEPTED 20 March 2023
PUBLISHED 29 March 2023

CITATION
Peng Y, Li Z, Fu Y, Pan Y, Zeng Y, Liu J,
Xiao C, Zhang Y, Su Y, Li G and Wu F
(2023) Corrigendum: Progress and
perspectives of perioperative
immunotherapy in non-small cell lung
cancer.
Front. Oncol. 13:1163376.
doi: 10.3389/fonc.2023.1163376

COPYRIGHT
© 2023 Peng, Li, Fu, Pan, Zeng, Liu, Xiao,
Zhang, Su, Li and Wu. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Corrigendum: Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer

Yurong Peng^{1†}, Zhuo Li^{2†}, Yucheng Fu¹, Yue Pan¹, Yue Zeng¹,
Junqi Liu¹, Chaoyue Xiao¹, Yingzhe Zhang¹, Yahui Su³,
Guoqing Li³ and Fang Wu^{1*}

¹Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China, ²The Ophthalmologic Center of the Second Xiangya Hospital, Central South University, Changsha, Hunan, China, ³XiangYa School of Public Health, Central South University, Changsha, Hunan, China

KEYWORDS

perioperative period perioperative immunotherapy, neoadjuvant therapies, immunotherapy, neoadjuvant immune monotherapy, adjuvant therapy, biomarkers, NSCLC, lung cancer

A corrigendum on

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer

by Peng Y, Li Z, Fu Y, Pan Y, Zeng Y, Liu J, Xiao C, Zhang Y, Su Y, Li G and Wu F (2023)
Front. Oncol. 13:1011810. doi: 10.3389/fonc.2023.1011810

In the published article, two figures (1 and 2) were accidentally omitted but were subject to peer review and included in the original submission. The figures and respective citations have been added to the original article. [Figure 1](#) has been cited at the end of **1 Introduction** and [Figure 2](#) has been cited at the end of the **6 Discussion**. The missing figure and their captions appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 1
 Biomarkers of perioperative immunotherapy. TME, Tumor microenvironment. IL-8, interleukin-8. TGF-β, Transforming growth factor. IL-6, interleukin-6. ILT-2, Ig-like transcript 2. TLS, Tertiary lymphoid structures. TIL, tumor-infiltrating lymphocytes. EGFR, epidermal growth factor receptor. HLA, human leukocyte antigen. PD-1, programmed cell death protein 1. PD-L1, Programmed cell death ligand 1. HRD, Homologous recombination deficiency. DDR, DNA-damage response/HR, homologous recombination pathway, MMR, mismatch repair. MSI, microsatellite instability. TMB, tumor mutation burden. KMT2A/B/C, Lysine methyltransferase 2A/B/C. POLE, polymerase epsilon. DNMT3A, DNA methyltransferases 3A. BMI, body mass index. CEA, carcinoembryonic antigen. NK, natural killer cells. AKK, Akkermansia muciniphila. NK, natural killer cells. CD4, cluster of differentiation 4. CD8+, cluster of differentiation 8. Treg, regulatory T cells. DC, dendritic cells. CTL, cytotoxic T lymphocyte.




FIGURE 2
 The Phase III clinical trials of different modes of perioperative immunotherapy for Non-Small Cell Lung Cancer. CT, chemotherapy.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.